151 related articles for article (PubMed ID: 8770236)
1. ICRF-193 modifies etoposide-induced apoptosis in thymocytes.
Tanimoto C; Hirakawa S; Kawasaki H; Hayakawa N; Ota Z
Acta Med Okayama; 1995 Dec; 49(6):281-6. PubMed ID: 8770236
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
Kizaki H; Onishi Y
Adv Enzyme Regul; 1997; 37():403-23. PubMed ID: 9381984
[TBL] [Abstract][Full Text] [Related]
3. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
Beere HM; Chresta CM; Hickman JA
Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
[TBL] [Abstract][Full Text] [Related]
6. Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange.
Hamatake M; Andoh T; Ishida R
Anticancer Drugs; 1997 Jul; 8(6):637-42. PubMed ID: 9300580
[TBL] [Abstract][Full Text] [Related]
7. bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis.
Onishi Y; Azuma Y; Kizaki H
Biochem Mol Biol Int; 1994 Jan; 32(1):115-22. PubMed ID: 8012276
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action.
Pérez C; Vilaboa NE; García-Bermejo L; de Blas E; Creighton AM; Aller P
J Cell Sci; 1997 Feb; 110 ( Pt 3)():337-43. PubMed ID: 9057086
[TBL] [Abstract][Full Text] [Related]
9. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
10. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule.
Ishida R; Iwai M; Hara A; Andoh T
Anticancer Res; 1996; 16(5A):2735-40. PubMed ID: 8917380
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Adachi N; Suzuki H; Iiizumi S; Koyama H
J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
Suzuki H; Tarumoto Y; Ohsawa M
Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis of unstimulated human lymphocytes and DNA strand breaks induced by the topoisomerase II inhibitor etoposide (VP-16).
Tronov VA; Konoplyannikov MA; Nikolskaya TA; Konstantinov EM
Biochemistry (Mosc); 1999 Mar; 64(3):345-52. PubMed ID: 10205305
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T
Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of epipodophyllotoxin-induced thymocyte apoptosis: possible role of a novel Ca(2+)-independent protein kinase.
Ye X; Georgoff I; Fleisher S; Coffman FD; Cohen S; Fresa KL
Cell Immunol; 1993 Oct; 151(2):320-35. PubMed ID: 8402939
[TBL] [Abstract][Full Text] [Related]
16. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
Fattman CL; Allan WP; Hasinoff BB; Yalowich JC
Biochem Pharmacol; 1996 Aug; 52(4):635-42. PubMed ID: 8759037
[TBL] [Abstract][Full Text] [Related]
17. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex.
Gantchev TG; Hunting DJ
Mol Pharmacol; 1998 Mar; 53(3):422-8. PubMed ID: 9495807
[TBL] [Abstract][Full Text] [Related]
18. Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells.
Kobayashi M; Adachi N; Aratani Y; Kikuchi A; Koyama H
Cancer Lett; 2001 May; 166(1):71-7. PubMed ID: 11295289
[TBL] [Abstract][Full Text] [Related]
19. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin-dependent enzymes.
Aoyama M; Grabowski DR; Holmes KA; Rybicki LA; Bukowski RM; Ganapathi MK; Ganapathi R
Biochem Pharmacol; 2001 Jan; 61(1):49-54. PubMed ID: 11137708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
